Bris­tol My­ers Squibb walks on Op­di­vo's FDA nod for small-cell lung can­cer af­ter mid­dling OS da­ta could­n't back ap­proval

In a pitched bat­tle against Mer­ck’s Keytru­da, Bris­tol My­ers Squibb’s im­munother­a­py head­lin­er Op­di­vo land­ed a ma­jor sal­vo with a ground­break­ing FDA ap­proval for cer­tain lung can­cer pa­tients back in 2018. Since that nod, how­ev­er, Op­di­vo has turned out clin­i­cal duds in that mar­ket, and now Bris­tol is cut­ting its loss­es.

Bris­tol has agreed to give up Op­di­vo’s third-line-or-lat­er FDA ap­proval for small-cell lung can­cer af­ter con­fir­ma­to­ry tri­als for an ac­cel­er­at­ed nod in that in­di­ca­tion back in 2018 failed to show ben­e­fit in ex­tend­ing pa­tients’ lives, the drug­mak­er said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER